Researchers used focused ultrasound to neuromodulate the inflammatory pathways in the spleen that contribute to the development of pulmonary hypertension.
This preclinical work highlights the spleen’s role in regulating the body’s immune reaction to pulmonary hypertension.
HistoSonics’ #HOPE4LIVER clinical trial results proved the treatment is safe, leading the US FDA to clear its Edison system for the treatment of liver tumors.
The company also launched a new website to help patients learn more about histotripsy and find a treatment site.
The Research Program Manager will oversee Foundation-funded preclinical research projects and assist with the funding proposal process and organizing workshops, roundtables, and webinars.
Qualified applicants must have a PhD, DVM, or MD degree.
Norman Spivak is an MD/PhD student conducting research on low-intensity focused ultrasound neuromodulation for treating disorders in psychiatry and neurosurgery.
Learn more about his work and where he sees the future of focused ultrasound neuromodulation.
In this video blog, the Foundation’s Director of Commercial Initiatives and Strategy shares insights into focused ultrasound product development and fundraising.
The vlog is intended for existing company leaders and entrepreneurs who are considering starting their own company.
The company’s software – called Optim MRI – helps neurosurgeons identify operable brain regions in patients with Parkinson’s disease and essential tremor.
The new clearance expands Optim MRI's capabilities to include the inferolateral part of the VIM region of the brain.
“All of a sudden, my arms went completely still. And the overwhelming sensation of violently having tremors for the past 10 years — and then their going completely away — was an uncontrollable emotion.”
‒ Bobby Krause, after undergoing focused ultrasound for his Parkinson’s disease